c-raf-1 Depletion and tumor responses in patients treated with the c- raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A)

Clinical Cancer Research

Volumn 5, Issue 12, 1999, Pages 3977-3982

  O'Dwyer, Peter J ^a,c   Stevenson, James P ^a   Gallagher, Maryann ^a   Cassella, Amy ^a   Vasilevskaya, Irina ^a   Monia, Brett P ^b   Holmlund, Jon ^b   Dorr, F Andrew ^b   Yao, Kang Shen ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARCINOEMBRYONIC ANTIGEN; CGP 69846A; EDRECOLOMAB; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 2; IRINOTECAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; DOSE RESPONSE; FEMALE; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR GROWTH;

AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GROWTH INHIBITORS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-RAF; RNA, MESSENGER; THIONUCLEOTIDES;

EID: 0033378009     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Daum, G., Eisenmann-Tappe, I., Fries, H. W., Troppmair, J., and Rapp, U. R. The ins and outs of Raf kinases. Trends Biol. Sci., 19: 474-480, 1994.
2. Nishida, E., and Gotoh, Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biol. Sci., 18: 128-131, 1993.
3. Stokoe, D., MacDonald, S., Cadwallader, K., Symons, M., and Hancock, J. Activation of Raf as a result of recruitment to the plasma membrane. Science (Washington DC), 264: 1463-1467, 1994.
4. ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature (Lond.), 364: 308-313, 1993.
5. Cobb, M. H., and Goldsmith, E. J. How MAP kinases are regulated. J. Biol. Chem., 270: 14843-14846, 1996.
6. McCormick, F. Ras-related proteins in signal transduction and growth control. Mol. Reprod. Dev., 42: 500-506, 1995.
7. MAPK pathway. J. Biol. Chem., 271: 20608-20616, 1996.
8. Li, S., and Sedivy, J. M. Raf-1 protein kinase activates the NF-κB transcription factor by dissociating the cytoplasmic NF-κB-IκB complex. Proc. Natl. Acad. Sci. USA, 90: 9247-9251, 1993.
9. Wang, H-G., Rapp, U. R., and Reed, J. C. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell, 87: 629-638, 1996.
10. Bos, J. L. ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689, 1989.
11. ras. J. Biol. Chem., 268: 20232-20236, 1993.
12. Stokoe, D., and McCormick, F. Activation of c-Raf-1 by Ras and Src through different mechanisms: activation in vivo and in vitro. EMBO J., 16: 2384-2396, 1997.
13. Stancato, L. F., Yu, C. R., Petricoin, E. F., III, and Larner, A. C. Beta interferon and oncostatin M activate raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway. Mol. Cell. Biol., 17: 3833-3840, 1997.
14. Kolch, W., Heidecker, G., Kochs, G., Hummel, R., Vahidi, H., Mischak, H., Finkenzeller, G., Marme, D., and Rapp, U. R. Protein kinase Cα activates Raf-1 by direct phosphorylation. Nature (Lond.), 364: 249-252, 1993.
15. Ueda, Y., Hirai, S., Osada, S., Suzuki, A., Mizuno, K., and Ohno, S. Protein kinase Cδ activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J. Biol. Chem., 271: 23512-23519, 1996.
16. Yao, B., Zhang, Y., Delikat, S, Mathias, S., Basu, S., and Kolesnick, R. Phosphorylation of Raf by ceramide-activated protein kinase. Nature (Lond.), 378: 307-310, 1995.
17. Farrar, M. A., Alberola-Ila, J., and Perlmutter, R. M. Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization. Nature (Lond.), 383: 178-181, 1996.
18. Stanton, V. P., Jr., and Cooper, G. M. Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences. Mol. Cell. Biol., 7: 1171-1179, 1987.
19. Storm, S. M., and Rapp, U. R. Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol. Lett., 67: 201-210, 1993.
20. Monia, B. P., Sasmor, H., Johnston, J. F., Freier, S. M., Lesnik, E. A., Muller, M., Geiger, T., Altmann, K. H., Moser, H., and Fabbro, D. Sequence-specific antitumor activity of a phosphorothioale oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. Sci. USA, 93: 15481-15484, 1996.
21. Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., and Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-raf kinase. Nat. Med., 2: 668-675, 1996.
22. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
23. Horikoshi, T., Danenberg, K. D., Stadlbauer, T. H., Volkenandt, M., Shea, L. C., Aigner, K., Gustavsson, B., Leichman, L., Frosing, R., Ray, M., Gibson, N. W., Spears, C. P., and Danenberg, P. V. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res., 52: 108-116, 1992.
24. O'Dwyer, P. J., Szarka, C. E., Yao, K. S., Halbherr, T. C., Pfeiffer, G. R., Green, F., Gallo, J. M., Brennan, J., Frucht, H., Goosenberg, E. B., Hamilton, T. C., Litwin, S., Balshem, A. M., Engstrom, P. F., and Clapper, M. L. Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. J. Clin. Investig., 98: 1210-1217, 1996.
25. Stevenson, J. P., Yao, K-S., Gallagher, M., Friedland, D., Mitchell, E. P., Cassella, A., Monia, B., Kwoh, T. J., Yu, R., Holmlund, J., Dorr, F. A., and O'Dwyer, P. J. Phase 1 clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J. Clin. Oncol., 17: 2227-2236, 1999.
26. Parsons, R., Myeroff, L. L., Liu, B., Willson, J. K., Markowitz, S. D., Kinzler, K. W., and Vogelstein B. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res., 55: 5548-5550, 1995.
27. Henry, S. P., Monteith, D., and Levin, A. A. Antisense oligonucleotide inhibitors for the treatment of cancer. 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Des., 12: 395-408, 1997.
28. Henry, S. P., Monteith, D., Bennett, F., and Levin, A. A. Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-α and c-raf kinase. Anti-Cancer Drug Des., 12: 409-420, 1997.
29. Levine, S. A., Sivulich, M., Wiernik, P. H., and Levy, H. B. Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer. Cancer Res., 39: 1645-1650, 1979.
30. Bishop, M. R., Iversen, P. L., Bayever, E., Sharp, J. G., Greiner, T. C., Copple, B. L., Ruddon, R., Zon, G., Spinolo, J., Arneson, M., Armitage, J. O., and Kessinger, A. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. Clin. Oncol., 14: 1320-1326, 1996.
31. Glover, J. M., Leeds, J. M., Mant, T. G., Amin, D., Kisner, D. L., Zuckerman, J. E., Geary, R. S., Levin, A. A., and Shanahan, W. R., Jr. Phase I safety and pharmacokinetic profile of an intracellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J. Pharmacol. Exp. Ther., 282: 1173-1180, 1997.
32. Perez, J. R., Higgins-Sochaski, K. A., Maltese, J-Y., and Narayanan, R. Antisense rel A in cancer. In: S. Agrawal (ed.), Methods in Molecular Medicine: Antisense Therapeutics, pp. 183-199. Totowa: Humana Press, Inc., 1996.
33. Bargou, R. C., Jurchott, K., Wagener, C., Bergmann, S., Metzner, S., Bommert, K., Mapara, M. Y., Winzer, K. J., Dietel, M., Dorken, B., and Royer, H. D. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat. Med., 4: 447-450, 1997.
34. Geary, R. S., Leeds, J. M., Henry, S. P., Monteith, D. K., and Levin, A. A. Antisense oligonucleotide inhibitors for the treatment of cancer. I. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Des., 12: 383-393, 1997.
35. Dumontet, C., Duran, G. E., Steger, K. A., Beketic-Oreskovic. L., and Sikic, B. I. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res., 56: 1091-1097, 1996.
36. Benimetskaya, L., Loike, J. D., Khaled, Z., Loike, G., Silverstein, S. C., Cao, L., el Khoury, J., Cai, T. Q., and Stein, C. A. Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nat. Med., 3: 414-420, 1997.
37. Stein, C. A. Does antisense exist? Nat. Med., 1: 1119-1121, 1995.
38. Stein, C. A., and Krieg, A. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res. Dev., 4: 67-69, 1994.
39. Crooke, S. T. Proof of mechanism of antisense drugs. Antisense Nucleic Acid Drug Dev., 6: 145-147, 1996.
40. McIntyre, K. W., Lombard-Gillooly, K., Perez, J. R., Kunsch, C., Sarmiento, U. M., Larigan, J. D., Landreth, K. T., and Narayanan, R. A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-κB p65 causes sequence-specific immune stimulation. Antisense Res. Dev., 3: 309-322, 1993.
41. Branda, R. F., Moore, A. L., Mathews, L., McCormack, J. J., and Zon, G. Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem. Pharmacol., 45: 2037-2043, 1993.
42. Mojcik, C. F., Gourley, M. F., Klinman, D. M., Krieg, A. M., Gmelig-Meyling, F., and Steinberg, A. D. Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects in vivo in a sequence-specific manner. Clin. Immunol. Immunopathol., 67: 130-137, 1993.
43. Wagner, R. W. Gene inhibition using antisense oligodeoxynucleotides. Nature (Lond.), 372: 333-335, 1994.
44. Boggs, R. T., McGraw, K., Condon, T., Flournoy, S., Villiet, P., Bennett, C. F., and Monia, B. P. Characterization and modulation of immune stimulation by modified oligonucleotides. Antisense Nucleic Acid Drug Dev., 7: 461-471, 1997.
45. Holmlund, J., Nemunaitis, J., Schiller, J., Dorr, A., and Kisner, D. Phase I trial of c-raf antisense oligonucleotide ISIS 5132 (CGP 69846A) by 21-day continuous intravenous infusion (CIV) in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol., 17: 210a, 1998.